Vyant Bio, Inc.: management transactions · United States · SEC (Form 4)

About Vyant Bio, Inc.

Vyant Bio, Inc. is a U.S.-based biotechnology company historically associated with the NASDAQ market under the ticker VYNT, with principal offices in Cherry Hill, New Jersey, United States. The company’s core identity was built around a central nervous system (CNS) drug-discovery platform that combines human-derived biology, brain-disease organoid models, scaled biology, and machine-learning tools to identify, validate, and prioritize therapeutic targets. Its research focus has centered on difficult neurodevelopmental and neurodegenerative disorders, including Rett syndrome, CDKL5 deficiency disorder, and familial Parkinson’s disease. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1349929/000149315223029043/formdef14a.htm)) From a corporate history perspective, Vyant Bio developed as a translational biotech platform aimed at improving early-stage drug discovery through human-relevant models and data science. Over time, the company also owned and operated vivoPharm, but later sold that business and narrowed its focus toward CNS-related therapeutic programs. In 2023, management announced a reduction in force and began exploring strategic alternatives, framing the process as an effort to preserve cash and maximize shareholder value, while retaining the possibility of an orderly wind-down if no suitable transaction emerged. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1349929/000149315223029043/formdef14a.htm)) In competitive terms, Vyant Bio sits within the highly crowded and capital-intensive universe of small-cap biotech drug-discovery companies. Its differentiated proposition was the integration of artificial intelligence, machine learning, and human organoid biology to de-risk candidate selection and improve the quality of downstream clinical hypotheses. At the same time, the company has disclosed that it had no approved products and no product-sales revenue, which means its valuation case has depended primarily on platform value, intellectual property, and corporate optionality rather than commercial execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1349929/000149315223029043/formdef14a.htm)) For investors, especially those in French-speaking markets looking at U.S. small caps, the key message is that Vyant Bio represents a distressed or turnaround-style biotechnology profile rather than a conventional growth biotech. The most important recent developments were the company’s cash-preservation initiative, the suspension of most preclinical and clinical activity, and its voluntary delisting from NASDAQ in April 2023, with shares expected to trade on the OTC Pink market thereafter. Those steps marked a major strategic reset and materially changed the risk-reward profile versus a normal listed biotech issuer. ([globenewswire.com](https://www.globenewswire.com/news-release/2023/04/24/2653390/0/en/Vyant-Bio-Announces-Voluntary-Nasdaq-Delisting-and-SEC-Deregistration.html))